A federal judge in the United States denied Bayer’s request for an injunction to block Johnson & Johnson’s advertising claims about its prostate‑cancer drug Erleada. The ruling, issued on Friday, April 18, 2026, found that Bayer’s allegations of false advertising were not supported by the evidence presented, allowing J&J to continue promoting its product without a court‑ordered restriction.
The dispute centers on the use of real‑world evidence versus traditional clinical trials to support marketing claims. J&J argues that its retrospective analysis shows a 51% reduction in the risk of death with Erleada compared to Bayer’s Nubeqa, while Bayer contends the analysis is methodologically flawed, citing imbalances in patient cohorts, insufficient follow‑up, and off‑label use of Nubeqa during the study period.
In 2025, Erleada generated $3.57 billion in sales, while Nubeqa achieved €2.39 billion ($2.81 billion). Bayer has set peak sales targets for Nubeqa exceeding €3 billion ($3.4 billion). These figures illustrate the intense competition between the two drugs in the non‑metastatic castration‑resistant prostate‑cancer market, where both products have secured significant market share and revenue streams.
Johnson & Johnson said, “This is a win for scientific exchange and a strong win for patients. Real‑world evidence helps clinicians make informed treatment decisions, especially when head‑to‑head clinical trial data are not available.” Bayer spokeswoman Sue Ann Pentecost stated, “Bayer continues to believe the full body of evidence supports its false advertising claims and looks forward to the court’s determination on the merits of the case.”
The ruling removes a potential legal barrier that could have restricted J&J’s marketing of Erleada, preserving the company’s competitive position and eliminating a significant regulatory risk. However, Bayer has indicated it will pursue the case on its merits, meaning the legal battle is far from over and could influence future marketing strategies and market dynamics in the prostate‑cancer drug sector.
No immediate market reaction data were reported in the sources available.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.